Group B Streptococcus prophylaxis in labor and delivery

Group B Streptococcus (GBS), also called Streptococcus agalactiae, can live harmlessly in the gastrointestinal and genital tracts of healthy adults. During labor, however, a colonized parent may transmit the organism to the newborn. Most exposed infants remain well, but some develop early-onset disease, including bacteremia, pneumonia, or meningitis during the first days of life.

The central prevention strategy is targeted intravenous antibiotic treatment during labor. This approach does not attempt to eliminate long-term colonization before birth. Instead, it reduces the number of bacteria present around the time of delivery, when exposure is most likely. Effective care depends on screening, accurate documentation, timely medication, and communication between prenatal and birth teams.

Perinatal clinicians also need to distinguish GBS prevention from evaluation of maternal infection. Fever, hypotension, uterine tenderness, altered mental status, or other signs of sepsis require urgent assessment and broad management rather than relying on GBS prophylaxis alone. The FAOPS 2020 archive offers historical context for the international perinatal medicine community and its interest in neonatal infection prevention.

Why GBS prevention matters at birth

GBS is transmitted most often during labor or after rupture of the membranes. A newborn may acquire the organism while passing through the birth canal, or bacteria may ascend after the membranes rupture. Early-onset GBS disease usually appears within the first 24 hours, although surveillance definitions commonly include illness during the first six days of life.

Risk is higher when the pregnant patient has documented GBS colonization, GBS bacteriuria during the current pregnancy, or a previous infant with invasive GBS disease. Premature birth, prolonged rupture of membranes, and intrapartum fever also increase concern. These factors do not all carry the same clinical meaning, so the care team should use a formal protocol rather than an informal risk estimate.

Intrapartum antibiotics have a specific purpose: preventing early-onset neonatal infection. They do not reliably prevent late-onset disease, which occurs from seven days through several months of age and may involve community or household transmission. Parents should receive clear information about warning signs in the newborn, including poor feeding, breathing difficulty, temperature instability, lethargy, and unusual irritability.

Screening and identifying patients who need treatment

In many healthcare systems, a vaginal-rectal culture is collected late in pregnancy, commonly between 36 weeks 0 days and 37 weeks 6 days. The result should be available in the birth record and transferred with the patient if labor occurs at another facility. A positive culture generally indicates the need for intrapartum antibiotic prophylaxis, even when the patient has no symptoms.

GBS bacteriuria at any concentration during the current pregnancy is clinically important. It indicates heavy colonization and means that antibiotics should be given during labor; a separate late-pregnancy screening culture is usually unnecessary for deciding prophylaxis. A previous infant with GBS disease is another indication for treatment in labor because recurrence risk is meaningful.

When screening results are unavailable, clinicians assess whether an indication for empiric prophylaxis exists. Common situations include preterm labor, rupture of membranes for 18 hours or longer at term, intrapartum temperature of at least 38°C, or an unknown status combined with other risk factors. A patient with a planned cesarean birth before labor and before membrane rupture generally does not require GBS-specific prophylaxis, although routine surgical antibiotic policy still applies.

Selecting an antibiotic safely

Penicillin G is the preferred medication for most patients. A commonly used regimen begins with a 5-million-unit intravenous loading dose, followed by 2.5 to 3 million units every four hours until birth. Ampicillin is an accepted alternative in many protocols, often given as a 2-g loading dose followed by 1 g every four hours. Local guidelines, formularies, and renal considerations should be checked before prescribing.

A reported penicillin allergy requires clarification rather than an automatic switch to a broad-spectrum drug. The clinician should document the reaction, timing, severity, and whether it involved anaphylaxis, angioedema, respiratory compromise, or severe skin disease. For patients with a low-risk allergy history, cefazolin is commonly recommended because it provides effective activity against GBS and has limited broader antimicrobial impact.

Patients at high risk for anaphylaxis need susceptibility-directed therapy. Clindamycin should be used only when the isolate is susceptible and appropriate resistance testing has been performed. Because resistance is common and inducible resistance can complicate interpretation, a laboratory report should specifically address the required testing. Vancomycin is generally reserved for situations in which the isolate is not suitable for clindamycin or susceptibility is unavailable in a high-risk allergy scenario.

Timing treatment around labor and birth

The ideal goal is to administer antibiotics at least four hours before delivery, since adequate exposure gives the medication time to reduce maternal and neonatal bacterial burden. Birth rarely follows a predictable schedule, however. Two hours of treatment is beneficial, and even a shorter interval may provide some protection. A patient should not be denied appropriate prophylaxis simply because delivery may occur soon.

Obstetric care must never be delayed solely to complete four hours of antibiotics. Necessary induction, operative birth, assisted delivery, or management of fetal compromise should proceed according to clinical need. The team should give the first dose as soon as the indication is recognized, repeat it according to the prescribed interval, and record the time, dose, route, allergy assessment, and birth outcome.

Rupture of membranes and preterm labor require coordinated decisions. If a patient with unknown GBS status presents in preterm labor, antibiotics may be indicated while clinicians manage prematurity and evaluate possible infection. If fever occurs during labor, the team should consider intra-amniotic infection and begin treatment appropriate to that diagnosis; GBS prophylaxis alone is not sufficient.

Managing unusual results and special circumstances

A negative screening culture is reassuring only within its valid clinical window and when no overriding indication exists. A prior infant with GBS disease or current-pregnancy GBS bacteriuria still supports prophylaxis. Documentation should make the reason for treatment visible so that a change in shift or facility does not lead to missed medication.

A positive rapid test obtained during labor may be useful when no prenatal culture is available, but testing should not delay treatment when clinical indications are already present. Point-of-care methods differ in sensitivity, and a negative result may not fully exclude colonization. Each maternity service should define how rapid results are interpreted and communicated to the newborn team.

Newborn management depends on gestational age, clinical condition, maternal temperature, rupture duration, antibiotic exposure, and the suspected diagnosis. A well-appearing infant may require observation rather than automatic laboratory testing, while a symptomatic infant needs immediate evaluation and empiric treatment according to neonatal protocols. Maternal antibiotics reduce risk but do not replace careful newborn assessment.

Maternal deterioration deserves special attention. Chills, tachycardia, low blood pressure, confusion, or rapidly worsening pain may indicate sepsis from GBS or another pathogen. Resources on maternal sepsis recognition reinforce the need to identify systemic illness promptly and escalate care without narrowing the diagnosis prematurely.

Building a reliable prevention system

The safest program treats GBS prevention as a workflow rather than a single prescription. Prenatal records should show the culture result, allergy status, bacteriuria history, prior neonatal history, and planned birth setting. At admission, staff should verify these details and flag missing results before labor becomes advanced.

Antibiotic stewardship matters because many patients receive antibiotics during pregnancy or birth for unrelated reasons. Narrow-spectrum penicillin or ampicillin is preferred when appropriate. Clindamycin and vancomycin should be reserved for patients who genuinely need them, with allergy histories and microbiology results reviewed carefully.

Hospitals can monitor the percentage of eligible patients who receive the first dose promptly, the frequency of inappropriate broad-spectrum therapy, and the number of newborns requiring evaluation for early-onset infection. Reviewing missed opportunities after delivery can reveal problems with laboratory reporting, transfer documentation, medication availability, or staff education.

Practical steps for maternity teams include:

• Make GBS status and penicillin allergy assessment mandatory admission fields.
• Use an electronic order set with weight, renal, allergy, and dosing prompts.
• Establish a clear pathway for cultures requiring clindamycin susceptibility testing.
• Record the time of membrane rupture, first antibiotic dose, repeat doses, and birth.
• Pair maternal prophylaxis with structured newborn observation and escalation criteria.

Consistent prevention depends on coordination among obstetricians, midwives, nurses, microbiology staff, pharmacists, and neonatologists. The objective is a prompt, evidence-based response that protects the newborn while avoiding unnecessary exposure to broad-spectrum antibiotics. Review local epidemiology and governing guidance regularly, since recommendations and resistance patterns can change.

At every birth admission, verify the screening history, clarify antibiotic allergies, start indicated prophylaxis without avoidable delay, and communicate the treatment record to the newborn team. That disciplined process turns GBS prevention from a documentation task into dependable protection for mothers and infants.